ArticleFrontiers in oncology2026
Factors associated with clinical research participation among Medicare beneficiaries with prostate cancer in the United States.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Introduction: Clinical research participation among patients with prostate cancer remains limited, and demographic, clinical, and contextual factors may influence opportunities for participation. Although disparities in prostate cancer diagnosis and treatment are well documented, less is known about the factors associated with clinical research participation in this population. This study examined patient-level and contextual factors associated with clinical research participation among older Medicare beneficiaries with prostate cancer. Methods: A retrospective claims-based analysis was conducted using the Medicare 5% Standard Analytical Files to identify men aged ≥65 years with a healthcare encounter for prostate cancer between January 1, 2016 and December 31, 2021. Clinical research participation was identified using the International Classification of Diseases, Tenth Revision, Clinical Modification diagnosis code Z00.6 ("Encounter for examination for normal comparison and control in clinical research program"). Deidentified patient-level data were linked to 2020 county-level social determinants of health (SDOH) data from the Agency for Healthcare Research and Quality database. Multivariable logistic regression models were used to evaluate demographic, clinical, and county-level contextual factors associated with clinical research participation. Results: A total of 107,250 Medicare Fee-for-Service (FFS) beneficiaries with prostate cancer were identified, representing approximately 2.145 million FFS beneficiaries after standard extrapolation. Among this cohort, 4,361 (4.07%) beneficiaries had documented clinical research participation, corresponding to approximately 87,220 beneficiaries after extrapolation. Compared to beneficiaries without documented research participation, beneficiaries participating in clinical research were younger, more often White, had higher Charlson Comorbidity Index (CCI) scores, and higher rates of metastatic disease. Residence in counties with higher socioeconomic indicators, including higher median household income, lower unemployment, higher educational attainment, and greater internet access was also associated with clinical research participation. After controlling for age, race, and CCI score, adjusted analyses identified several patient-level clinical and geographic characteristics, as well as county-level contextual characteristics, associated with clinical research participation, including metastatic disease, census region, county-level median household income, and county-level median distance to the nearest emergency department. Discussion: These findings suggest that patient- and community-level factors may influence participation in clinical research. Targeted efforts to reduce structural and geographic barriers may help promote more equitable participation in clinical research among prostate cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.